AbbVie Acquires Gilgamesh’s $1.2B Psychedelic Antidepressant Program to Tackle Major Depression

North Chicago, IL and New York, August  25, 2025 (PRNewswire) -- AbbVie will acquire Gilgamesh’s bretisilocin program for up to $1.2 billion, adding a next-generation psychedelic candidate for major depressive disorder to its neuroscience portfolio. Phase 2a results showed the drug produced a robust, statistically significant antidepressant effect with a shorter psychoactive duration and strong tolerability. The deal, which includes a spin-off of Gilgamesh’s remaining pipeline, positions AbbVie to accelerate late-stage development in psychiatric care.

Read full article here.